Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Cash & Equivalents (2016 - 2025)

Protalix BioTherapeutics has reported Cash & Equivalents over the past 16 years, most recently at $702000.0 for Q4 2025.

  • Quarterly results put Cash & Equivalents at $702000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $702000.0 (changed N/A YoY), and the annual figure for FY2025 was $702000.0, changed.
  • Cash & Equivalents for Q4 2025 was $702000.0 at Protalix BioTherapeutics, down from $13.6 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for PLX hit a ceiling of $48.2 million in Q2 2023 and a floor of $702000.0 in Q4 2025.
  • Median Cash & Equivalents over the past 5 years was $19.8 million (2021), compared with a mean of $21.9 million.
  • Biggest five-year swings in Cash & Equivalents: soared 8841.51% in 2021 and later tumbled 63.13% in 2022.
  • Protalix BioTherapeutics' Cash & Equivalents stood at $39.0 million in 2021, then crashed by 56.11% to $17.1 million in 2022, then surged by 38.12% to $23.6 million in 2023, then grew by 15.97% to $27.4 million in 2024, then plummeted by 97.44% to $702000.0 in 2025.
  • The last three reported values for Cash & Equivalents were $702000.0 (Q4 2025), $13.6 million (Q3 2025), and $17.9 million (Q2 2025) per Business Quant data.